FR104, an Antagonist Anti‐CD28 Monovalent Fab' Antibody, Prevents Alloimmunization and Allows Calcineurin Inhibitor Minimization in Nonhuman Primate Renal Allograft. Issue 1 (8th December 2014)

• Record Type: Journal Article
• Authors: Poirier, N.; Dilek, N.; Mary, C.; Ville, S.; Coulon, F.; Branchereau, J.; Tillou, X.; Charpy, V.; Pengam, S.; Nerriere‐Daguin, V.; Hervouet, J.; Minault, D.; Le Bas‐Bernardet, S.; Renaudin, K.; Vanhove, B.; Blancho, G.
• Is Part Of: American journal of transplantation. Volume 15:Issue 1(2015:Jan.)
• Page Start: 88
• Page End: 100
• Publication Date: 2014-12-08
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.12964
• Languages: English
• ISSNs: 1600-6135

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajt12964-sec-0001" sec-type="section"> <p>Selective targeting of CD28 might represent an effective immunomodulation strategy by preventing T cell costimulation, while favoring coinhibition since inhibitory signals transmitted through CTLA‐4; PD‐L1 and B7 would not be affected. We previously showed <italic>in vitro</italic> and <italic>in vivo</italic> that anti‐CD28 antagonists suppress effector T cells while enhancing regulatory T cell (Treg) suppression and immune tolerance. Here, we evaluate FR104, a novel antagonist pegylated anti‐CD28 Fab' antibody fragment, in nonhuman primate renal allotransplantation. FR104, in association with low doses of tacrolimus or with rapamycin in a steroid‐free therapy, prevents acute rejection and alloantibody development and prolongs allograft survival. However, when FR104 was associated with mycophenolate mofetil and steroids, half of the recipients rejected their grafts prematurely. Finally, we observed an accumulation of Helios‐negative Tregs in the blood and within the graft after FR104 therapy, confirmed by Treg‐specific demethylated region DNA analysis. In conclusion, FR104 reinforces immunosuppression in calcineurin inhibitor (CNI)‐low or CNI‐free protocols, without the need of steroids. Accumulation of intragraft Tregs suggested the promotion of immunoregulatory mechanisms. Selective CD28 antagonists might become an alternative CNI‐sparing strategy to B7 antagonists for kidney transplant recipients.</p> </sec> </abstract>